arstechnica.com

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say - Ars Technica

The vaccine reportedly thwarted the cancer's return and spread.

This site doesn’t allow embedding inside another page — open it in a new tab. Your Weird rating still works from the top bar.